Please use this identifier to cite or link to this item:
|Title:||All-Trans-Retinoic Acid, Idarubicin, and IV Arsenic Trioxide as initial therapy in Acute Promyelocytic Leukemia (APML4)||Authors:||Iland, H.J.;Bradstock, K.F.;Supple, S.G.;Catalano, A.;Collins, M.;Hertzberg, M.;Browett, P.;Grigg, A.;Firkin, F.;Hugman, A.;Reynolds, J.;Di Iulio, J.;Tiley, Campbell ;Taylor, K.;Filshie, R.;Seldon, M.;Taper, J.;Szer, J.;Moore, J.;Bashford, J.;Seymour, J.F.||Issue Date:||Aug-2012||Source:||Volume 120, Issue 8, pp. 1570 - 1580||Journal title:||Blood||Abstract:||The treatment of acute promyelocytic leukemia has improved considerably after recognition of the effectiveness of all-trans-retinoic acid (ATRA), anthracycline-based chemotherapy, and arsenic trioxide (ATO). Here we report the use of all 3 agents in combination in an APML4 phase 2 protocol. For induction, ATO was superimposed on an ATRA and idarubicin backbone, with scheduling designed to exploit antileukemic synergy while minimizing cardiotoxicity and the severity of differentiation syndrome. Consolidation comprised 2 cycles of ATRA and ATO without chemotherapy, followed by 2 years of maintenance with ATRA, oral methotrexate, and 6-mercaptopurine. Of 124 evaluable patients, there were 4 (3.2%) early deaths, 118 (95%) hematologic complete remissions, and all 112 patients who commenced consolidation attained molecular complete remission. The 2-year rate for freedom from relapse is 97.5%, failure-free survival 88.1%, and overall survival 93.2%. These outcomes were not influenced by FLT3 mutation status, whereas failure-free survival was correlated with Sanz risk stratification (P[trend] = .03). Compared with our previously reported ATRA/idarubicin-based protocol (APML3), APML4 patients had statistically significantly improved freedom from relapse (P = .006) and failure-free survival (P = .01). In conclusion, the use of ATO in both induction and consolidation achieved excellent outcomes despite a substantial reduction in anthracycline exposure. This trial was registered at the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) as ACTRN12605000070639.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/222||DOI:||10.1182/blood-2012-02-410746||Pubmed:||http://www.ncbi.nlm.nih.gov/pubmed/22715121||ISSN:||1528-0020||Publicaton type:||Journal Article||Keywords:||Cancer
|Study or Trial:||Clinical Trial|
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Feb 6, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.